Clinical trials
Myelodysplastic Syndromes clinical trials
Below are recruiting myelodysplastic syndromes clinical trials, each written for real people, not researchers. We’re tracking 284 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07761533RecruitingPhase 1/Phase 2
PBSS1113 plus azacitidine for blood cancers
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
Hangzhou, ZhejiangAges 18 years+ - NCT05444348Recruiting
Communication and care-planning support for blood cancer patients
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
AalborgAges 18 years+ - NCT06471946RecruitingPhase 1/Phase 2
Stem cell transplant for older patients with high-risk MDS
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
Beijing, Beijing MunicipalityAges 70 years+ - NCT05925504RecruitingPhase 2
Lowering luspatercept dose for lower-risk myelodysplastic anemia
This Phase 2 study tests whether gradually lowering the dose of luspatercept can help people with lower-risk myelodysplastic syndromes (MDS) who have anemia. It may help reduce side effects while still improving blood counts or symptoms.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07006025RecruitingPhase 1
Oral THU-decitabine for MDS that has returned or not improved
This trial tests an oral combination of two drugs (THU and decitabine) for people with myelodysplastic syndromes (MDS) whose disease has come back or not responded to at least one prior standard treatment. The goal is to see if it can help control the disease.
The Bronx, New YorkAges 18 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT06788509Enrolling by invitationPhase 1
Continued treatment and safety monitoring after a parent study
This trial allows people who were already getting study treatment in a previous trial to keep receiving it and be monitored for safety. It is designed for those who have not had serious side effects or disease worsening.
Macquarie UniversityAges 18 years+ - NCT04093570Enrolling by invitationPhase 2
Extension study for people continuing ASTX727 from a prior trial
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
Fountain Valley, CaliforniaAges 18 years+ - NCT06987058Enrolling by invitationPhase 2
Continued RVU120 treatment study for current participants
This trial is for people who are already in a RVU120 study and have been receiving the drug for at least 5 cycles. It allows you to keep getting RVU120 if you are benefiting from it and don't have other treatment options.
GdanskAges 18 years+ - NCT05350748Recruiting
MDS study using detailed tests on blood and bone marrow
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
Bethesda, MarylandAges 1 day–120 years - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia or MDS
This trial tests a special type of cord blood transplant using lab-grown stem cells to help the new blood-forming cells “take” sooner. It’s for people with severe aplastic anemia or certain MDS cases who have not responded well to standard immune-suppressing treatments.
Bethesda, MarylandAges 4–75 - NCT03214562RecruitingPhase 1/Phase 2
Venetoclax plus chemotherapy for acute leukemia
This trial studies how well venetoclax combined with chemotherapy treats newly diagnosed or returning (relapsed) or hard-to-treat (refractory) acute myeloid leukemia (AML). It’s mainly for people who can’t use standard AML therapy well, or whose disease came back.
Houston, TexasAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT03520647RecruitingPhase 2
Haplo transplant for severe bone marrow failure using donor cells
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Bethesda, MarylandAges 4–75 - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03579875RecruitingPhase 2
Testing an inherited bone marrow transplant approach for rare blood disorders
This Phase 2 study tests a special “T-cell depleted” transplant plan for people with inherited bone marrow failure disorders (Fanconi anemia or T-Beta-thalassemia—or “TBD”). It may help restore healthy blood production while lowering the chance of certain transplant complications.
Minneapolis, MinnesotaAges Up to 65 years - NCT03589729RecruitingPhase 2
Dexrazoxane to help protect the heart during blood-cancer chemo
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
Houston, TexasAges 12 years+ - NCT03683433RecruitingPhase 2
Enasidenib plus azacitidine for IDH2-mutated AML
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
Houston, TexasAges 18 years+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT03964506RecruitingEarly Phase 1
Hyperbaric oxygen plus donor stem cell transplant for blood cancers
This early-phase trial studies whether breathing pure oxygen in a pressurized chamber, along with a donor stem cell transplant, can improve outcomes for certain blood cancers. It may help by supporting the body during transplant and recovery, but it is still being tested for safety and effectiveness.
Rochester, New YorkAges 18–75 - NCT03999723RecruitingPhase 2
Test azacitidine with vitamin C to improve DNA changes
This Phase 2 study tests whether combining azacitidine (a standard blood cancer medicine) with vitamin C helps improve disease control by changing DNA activity in high-risk blood cancers. It may be an option if you have certain types of higher-risk MDS, CMML, or low-blast AML and can meet safety requirements.
AalborgAges 18 years+
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myelodysplastic syndromes?
- Yes. Clin2 currently lists 284 recruiting myelodysplastic syndromes studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myelodysplastic syndromes trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myelodysplastic syndromes trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.